Patent · US Active

Anti-CLauDiN 18 antibodies and methods of use thereof

US11407828B2 · kind B2 · utility

0Cited by
28References
5Claims
0Family size

Assignee

Inventors

Key dates

Filing dateFeb 3, 2020
Grant dateAug 9, 2022
Priority date
Expiry dateFeb 3, 2040

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07K2317/92
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Antibodies that specifically bind to the human tight junction molecule CLDN18.2 and have functional properties that make them suitable for use in antibody-based immunotherapies of a disease associated with aberrant expression of CLDN18.2 are disclosed.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.